Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA4 | P22748 | 2/20 | 0.37 |
| ▸ | CA5A | P35218 | 2/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL4601512 | 1.00 | SLC34A1 (0.73) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL28894407 | 1.00 | SLC34A1 (0.73) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL724055 | 1.00 | SLC34A1 (0.73) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL28979871 | 1.00 | SLC34A1 (0.73) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL101070 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL40491 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL14656197 | 1.00 | SLC34A1 (0.73) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL4731817 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL8972786 | 1.00 | SLC34A1 (0.73) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL23091295 | 0.95 | SLC34A1 (0.67) | SLC34A1KDM4ECYP2C19KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069619-A1 | Treatment of Dry Eye Disease Using Mitochondrially Targeted Antioxidants | MITOTECH S A (LU) | 2026-03-12 | — | — | US | claimed |
| CN-120195259-A | High-temperature-resistant electromagnetic flaw detector and testing process | 中国石油天然气股份有限公司 | 2025-06-24 | — | — | CN | claimed |
| EP-4536200-A1 | TREATMENT OF DRY EYE DISEASE USING MITOCHONDRIALLY TARGETED ANTIOXIDANTS | Mitotech S.A. (LU) | 2025-04-16 | — | — | EP | claimed |
| CN-119174739-A | Preparation method and application of polydopamine drug-loaded nano-particles | 北京化工大学 | 2024-12-24 | — | — | CN | claimed |
| WO-2024099419-A1 | TRIAMCINOLONE ACETONIDE COMPOSITION AND PREPARATION METHOD THEREFOR | 北京华视诺维医疗科技有限公司 | 2024-05-16 | — | — | WO | claimed |
| CN-117965422-A | Cervical exfoliated cell sample density separating liquid and application method thereof | 武汉大学人民医院（湖北省人民医院） | 2024-05-03 | — | — | CN | claimed |
| WO-2023237902-A1 | TREATMENT OF DRY EYE DISEASE USING MITOCHONDRIALLY TARGETED ANTIOXIDANTS | MITOTECH S.A. (LU) | 2023-12-14 | — | — | WO | claimed |
| WO-2023197401-A1 | BIOLOGICAL GEL FORMULATION, METHOD FOR PREPARING SAME, AND USE THEREOF | 臻赫医药(杭州)有限公司 | 2023-10-19 | — | — | WO | claimed |
| CN-109991303-B | Method for rapidly identifying single flower honey by capillary electrophoresis technology | 北京工商大学 | 2023-10-03 | — | — | CN | claimed |
| CN-116660436-A | Method for measuring DMTMM residual quantity in crosslinked sodium hyaluronate gel | 上海昊海生物科技股份有限公司 | 2023-08-29 | — | — | CN | claimed |
| CN-110736796-B | Method for detecting molecular weight of pneumococcal capsular polysaccharide | 北京智飞绿竹生物制药有限公司 | 2022-07-01 | — | — | CN | claimed |
| CN-112852637-B | Korea haemolytica WYS377 and application thereof in laccase production | 中国科学院微生物研究所 | 2022-04-26 | — | — | CN | claimed |
| CN-113684171-A | Method and culture medium for improving microbial culture effect | 北京蓝晶微生物科技有限公司 | 2021-11-23 | — | — | CN | claimed |
| CN-111991241-B | 'donkey-like-mouth' flower spherical fluoridated hydroxyapatite-based dental composite resin and preparation method thereof | 东华大学 | 2021-11-09 | — | — | CN | claimed |
| CN-112852637-A | Korea haemolytica WYS377 and application thereof in laccase production | 中国科学院微生物研究所 | 2021-05-28 | — | — | CN | claimed |
| CN-109620842-B | Cross-linked polyvinylpyrrolidone and iodine complex, and preparation method and application thereof | 上海宇昂水性新材料科技股份有限公司 | 2021-05-04 | — | — | CN | claimed |
| CN-112616863-A | Disinfectant preparation process | 李慧 | 2021-04-09 | — | — | CN | claimed |
| CN-111991241-A | 'donkey-like-mouth' flower spherical fluoridated hydroxyapatite-based dental composite resin and preparation method thereof | 东华大学 | 2020-11-27 | — | — | CN | claimed |
| CN-111393219-A | Microbial fermented liquid fertilizer and application method thereof | 重庆大学 | 2020-07-10 | — | — | CN | claimed |
| CN-110736796-A | method for detecting molecular weight of pneumococcal capsular polysaccharide | 北京智飞绿竹生物制药有限公司 | 2020-01-31 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069619-A1 | Treatment of Dry Eye Disease Using Mitochondrially Targeted Antioxidants | SQOR, NDUFB1, MT-ND1 | SLC34A1 3076/4885KDM4E 3411/4885CYP2C19 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.